Tao Han1, Ying Liu, Huan Liu, Zheng-Yan Zhu, Yan Li, Shi-Xiang Xiao, Zhen Guo, Zhen-Gang Zhao. 1. Department of Hepatology, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Artificial Cells, Tianjin Third Central Hospital, Tianjin Medical University, 83 Jintang Road, Tianjin 300170, China. hantaomd@126.com
Abstract
AIM: To investigate whether serum thymosin beta4 can provide diagnostic or prognostic information in liver failure patients caused by chronic hepatitis B virus (HBV) infection. METHODS: Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls. Serum thymosin beta4 levels were measured by enzyme-linked immunosorbent assay and Child-Pugh and model for end-stage liver disease (MELD) scores were calculated for each patient on admission. RESULTS: Compared with healthy controls, serum thymosin beta4 levels in ACLF, CLF, CR and chronic hepatitis B patients were significantly lower, 6.5047 (4.7879-10.5314) microg/mL vs 0.4632 (0.2759-0.8768) microg/mL, 0.6981 (0.5209-1.2008) microg/mL, 1.8053 (0.8110-2.3397) microg/mL, 3.7803 (1.8570-6.4722) microg/mL, respectively (P < 0.001). The levels of thymosin beta4 in liver failure (ACLF or CLF) patients were markedly lower than that in CR (P < 0.001), and a difference was also found between CLF and ACLF patients (P = 0.038). In patients with chronic liver disease, there was a positive relationship between thymosin beta4 levels and albumin, choline esterase, and platelet (P < 0.001), and negative relationship with alanine aminotransferase (P = 0.020), aspartate aminotransferase, total bilirubin, international normalized ratio of prothrombin time, and Child-Pugh and MELD scores (P < 0.001). Of the 61 liver failure patients, the thymosin beta4 levels of non-survivors were significantly lower than that of survivors (P = 0.007). Receiver operating characteristics analysis identified a thymosin beta4 cutoff level of 0.5708 microg/mL for predicting poor prognosis in all liver failure patients. The serial thymosin beta4 values were observed in 13 liver failure inpatients. Lower initial values were observed in the death. While greater improvement in thymosin beta4 value was found in those who recovered from the disease. CONCLUSION: Serum thymosin beta4 can be used as an important potential predictor for liver failure caused by chronic HBV infection.
AIM: To investigate whether serum thymosin beta4 can provide diagnostic or prognostic information in liver failurepatients caused by chronic hepatitis B virus (HBV) infection. METHODS: Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls. Serum thymosin beta4 levels were measured by enzyme-linked immunosorbent assay and Child-Pugh and model for end-stage liver disease (MELD) scores were calculated for each patient on admission. RESULTS: Compared with healthy controls, serum thymosin beta4 levels in ACLF, CLF, CR and chronic hepatitis Bpatients were significantly lower, 6.5047 (4.7879-10.5314) microg/mL vs 0.4632 (0.2759-0.8768) microg/mL, 0.6981 (0.5209-1.2008) microg/mL, 1.8053 (0.8110-2.3397) microg/mL, 3.7803 (1.8570-6.4722) microg/mL, respectively (P < 0.001). The levels of thymosin beta4 in liver failure (ACLF or CLF) patients were markedly lower than that in CR (P < 0.001), and a difference was also found between CLF and ACLF patients (P = 0.038). In patients with chronic liver disease, there was a positive relationship between thymosin beta4 levels and albumin, choline esterase, and platelet (P < 0.001), and negative relationship with alanine aminotransferase (P = 0.020), aspartate aminotransferase, total bilirubin, international normalized ratio of prothrombin time, and Child-Pugh and MELD scores (P < 0.001). Of the 61 liver failurepatients, the thymosin beta4 levels of non-survivors were significantly lower than that of survivors (P = 0.007). Receiver operating characteristics analysis identified a thymosin beta4 cutoff level of 0.5708 microg/mL for predicting poor prognosis in all liver failurepatients. The serial thymosin beta4 values were observed in 13 liver failure inpatients. Lower initial values were observed in the death. While greater improvement in thymosin beta4 value was found in those who recovered from the disease. CONCLUSION: Serum thymosin beta4 can be used as an important potential predictor for liver failure caused by chronic HBV infection.
Authors: Mahnaz Badamchian; Mirela O Fagarasan; Robert L Danner; Anthony F Suffredini; Hadi Damavandy; Allan L Goldstein Journal: Int Immunopharmacol Date: 2003-08 Impact factor: 4.932
Authors: Ildiko Bock-Marquette; Santwana Shrivastava; G C Teg Pipes; Jeffrey E Thatcher; Allissa Blystone; John M Shelton; Cristi L Galindo; Bela Melegh; Deepak Srivastava; Eric N Olson; J Michael DiMaio Journal: J Mol Cell Cardiol Date: 2009-05 Impact factor: 5.000
Authors: Nicola Smart; Catherine A Risebro; Athalie A D Melville; Kelvin Moses; Robert J Schwartz; Kenneth R Chien; Paul R Riley Journal: Nature Date: 2006-11-15 Impact factor: 49.962
Authors: Mohamed A A Hussein; Hosni A M Hussein; Ali A Thabet; Karim M Selim; Mervat A Dawood; Ahmed M El-Adly; Ahmed A Wardany; Ali Sobhy; Sameh Magdeldin; Aya Osama; Ali M Anwar; Mohammed Abdel-Wahab; Hussam Askar; Elsayed K Bakhiet; Serageldeen Sultan; Amgad A Ezzat; Usama Abdel Raouf; Magdy M Afifi Journal: Cells Date: 2022-04-21 Impact factor: 7.666